REDHILL BIOPHAR/S(NASDAQ:RDHL)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a report issued on Tuesday, July 31st.
Receive News & Ratings for REDHILL BIOPHAR/S Daily
Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.
The analysts wrote, “We are maintaining our Buy rating on RedHill and our 12-month price target of $36.00 per ADS based on the average of two valuation methods: (1) price-sales multiple using 7x 2025 sales estimate discounted at 14%; and (2) price-earnings multiple analysis applying a 15x multiple to our 2025 estimated earnings also discounted at 14%. (1) commercial; (2) regulatory; (3) clinical; (4) partnership; (5) financial; and (6) intellectual property.””
Other equities analysts also recently issued reports about the stock. ValuEngine downgraded shares of REDHILL BIOPHAR/S from a “hold” rating to a “sell” rating in a research note on Monday, July 30th. LADENBURG THALM/SH SH began coverage on shares of REDHILL BIOPHAR/S in a research note on Monday, June 25th. They issued a “buy” rating and a $20.00 price target for the company. Finally, Zacks Investment Research raised shares of REDHILL BIOPHAR/S from a “hold” rating to a “buy” rating and set a $6.75 price target for the company in a research note on Saturday, May 12th. Two analysts have rated the stock with a sell rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $19.96.
NASDAQ RDHL traded down $0.05 during trading on Tuesday, hitting $7.15. 255,300 shares of the company’s stock traded hands, compared to its average volume of 160,596. The firm has a market cap of $136.57 million, a price-to-earnings ratio of -2.75 and a beta of 0.75. REDHILL BIOPHAR/S has a 12-month low of $4.30 and a 12-month high of $11.49.
A hedge fund recently raised its stake in REDHILL BIOPHAR/S stock. ARK Investment Management LLC grew its position in shares of REDHILL BIOPHAR/S (NASDAQ:RDHL) by 8.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 112,648 shares of the biotechnology company’s stock after buying an additional 8,894 shares during the quarter. ARK Investment Management LLC owned 0.53% of REDHILL BIOPHAR/S worth $961,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 20.46% of the company’s stock.
About REDHILL BIOPHAR/S
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs.
AI
